\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes EICThe EIC Tech to Market Programme (T2M) is part of the EIC Business Acceleration Services (BAS) and is targeted at EIC Pathfinder & Transition beneficiaries to support in their transition from lab to market. It provides tailored support to entrepreneurial researchers for the market deployment of research results. The Tech2Market Programme consists of two main strands:
All information on these programmes and how to apply for their upcoming activities can be found on the Tech to Market Programme webpage
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment
The Clean Industrial Deal is described as "a bold business plan to support the competitiveness and resilience of our industry." It aims to boost production in green industries, with special focus on energy-intensive industries - vital for European material production and decarbonization goals. 6 main elements The Deal presents measures to boost e... read more
Security Digital, Industry & Space Digital Europe
In Digital Europe, knowledge of the underlying EU policies and legislations is a key element when drafting a proposal, as they play an important role in the “relevance” evaluation criterion. Also for Horizon Europe Cluster 3 (Cybersecurity) and Cluster 4 (Digital), this knowledge can be handy for applicants. To support... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
